Tevogen Logo Notified.png
Tevogen Bio Secures $6 Million Series C Preferred Stock Investment
22 août 2024 09h00 HE | Tevogen Bio Inc
WARREN, N.J., Aug. 22, 2024 (GLOBE NEWSWIRE) -- Tevogen Bio Holdings Inc. (“Tevogen” or “Tevogen Bio”) (Nasdaq: TVGN), a clinical-stage specialty immunotherapy biotech pioneer developing...
FullLogo_Transparent_NoBuffer.png
Project Mosaic Launches to Bring “Biopsies” to ALS Drug Development
21 août 2024 13h10 HE | Project Mosaic
Project Mosaic is proud to announce the launch of a groundbreaking initiative aimed at revolutionizing ALS drug development.
Atyr_Logo.png
aTyr Pharma to Participate in September Investor Conferences
21 août 2024 08h00 HE | aTyr Pharma, Inc.
aTyr Pharma to Participate in September Investor Conferences
Olema_Oncology_HIGH RES LOGO.png
Olema Oncology to Participate in Morgan Stanley 22nd Annual Global Healthcare Conference
21 août 2024 07h00 HE | Olema Oncology
SAN FRANCISCO, Aug. 21, 2024 (GLOBE NEWSWIRE) -- Olema Pharmaceuticals, Inc. (“Olema”, “Olema Oncology”, Nasdaq: OLMA), a clinical-stage biopharmaceutical company focused on the discovery,...
Captura de pantalla 2023-11-10 082355 big.png
Lipella Pharmaceuticals Unveils Advanced Bladder Imaging Technique at ICICJ Conference
21 août 2024 05h00 HE | Lipella Pharmaceuticals Inc.
Lipella Pharmaceuticals Unveils Advanced Bladder Imaging Technique at ICICJ Conference
PanOmiQ
PanOmiQ Set’s New Benchmark with 100% Accuracy in Whole Genome Sequencing Testing
20 août 2024 09h48 HE | BioAro
BioAro's PanOmiQ achieves 100% accuracy in Whole Genome Sequencing, setting a new benchmark; a 15-day free trial of AI-powered software is now available.
ANEW MEDICAL, INC. Strengthens Intellectual Property Protection with U.S. Patent Issuance for Its Secreted RNA Splice Variant of the Human Klotho Gene Used for the Treatment of Neurodegenerative and Age-Related Diseases
15 août 2024 05h00 HE | ANEW MEDICAL, INC.
NEW YORK, Aug. 15, 2024 (GLOBE NEWSWIRE) -- ANEW MEDICAL, INC. (“ANEW” or “the Company”) (NASDAQ: WENA) a U.S. -based biotechnology company focused on developing cell and gene-based treatments for...
GENELUX-Final-Logo-Notagline.png
Genelux Corporation Reports Second Quarter 2024 Financial Results and Provides General Business Updates
14 août 2024 16h05 HE | Genelux Corporation
WESTLAKE VILLAGE, Calif., Aug. 14, 2024 (GLOBE NEWSWIRE) -- Genelux Corporation (NASDAQ: GNLX), a late clinical-stage immuno-oncology company, today announced financial results for the second...